Modelling response to HIV therapy without a genotype: An argument for viral load monitoring in resource-limited settings

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 605-607

  Revell, A D ^a   Wang, D ^a   Harrigan, R ^b   Hamers, R L ^c   Wensing, A M J ^d   Dewolf, F ^e   Nelson, M ^f   Geretti, A M ^g   Larder, B A ^a  

^a The HIV Resistance Response Database Initiative (RDI)   (United Kingdom)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c PharmAccess Foundation   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e STICHTING HIV MONITORING   (Netherlands)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Access; Antiretroviral therapy; Computational modelling; HIV AIDS

Indexed keywords

CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; ARTIFICIAL NEURAL NETWORK; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; NONHUMAN; PREDICTION; RANDOM FOREST; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; COMPUTER SIMULATION; DEVELOPING COUNTRY; DRUG MONITORING; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METHODOLOGY; REVIEW;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DEVELOPING COUNTRIES; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 77952572939     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq032     Document Type: Article

References (13)

1. WHO, UNAIDS, UNICEF. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. Geneva: WHO, 2008.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (2 December 2009, date last accessed).
3. Gazzard BG. on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
4. Gupta R, Hill A, Sawyer A et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 409-17.
5. Hosseinipour MC, van Oosterhout J, Weigel R et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-34.
6. Mugyenyi P, Walker S, Hakin J et al. on behalf of the DART Trial team. Impact of routine laboratory monitoring over 5 years after ART initiation, the DART Trial final results. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 2009. Abstract TuSS103, p. 101. International AIDS Society, Geneva, Switzerland.
7. Medina-Lara A, Kigozi J, Amurwon J et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial). In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 2009. Abstract TuSS104, p. 101. International AIDS Society, Geneva, Switzerland.
8. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 Revision. Geneva: WHO, 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines. pdf (2 December 2009, date last accessed).
9. Wang D, Larder B, Revell A et al. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med 2009; 47: 63-74.
10. Larder B, Wang D, Revell A et al. The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 2007, 12: 15-24.
11. Revell AD, Wang D, Harrigan R et al. Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy. Antivir Ther 2009; 14 Suppl 1: A38.
12. Larder BA, Gerretti AM, Monno L et al. Neural networks are more accurate predictors of virologic response to antiretroviral therapy than rules-based genotype interpretation systems. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 653, p. 282. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
13. Larder B, Wang D, Revell A et al. Computational models can accurately predict response to antiretroviral therapy without a genotype. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract H-894. American Society for Microbiology, Washington, DC, USA.